aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Intellia Therapeutics, founded in Cambridge, Massachusetts, is a biotechnology company dedicated to transforming the lives of patients with severe genetic diseases through innovative gene editing therapies. Their core mission is to develop potentially curative genome editing treatments using CRISPR technology. Intellia focuses on both in vivo and ex vivo therapies, aiming to address a wide range of genetically-based conditions.
Notable figures affiliated with Intellia include Brian Goff, who serves on the Board of Directors. The company has achieved significant milestones, such as presenting the first-ever clinical data from patients redosed with an investigational in vivo CRISPR gene editing therapy. Intellia's pioneering work has had a substantial impact on the biotechnology field, pushing the boundaries of what is possible in genetic disease treatment.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Therapies, Gene Editing
Technology
Biotech, GenAI
Model Types
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Intellia Therapeutics founded?
Intellia Therapeutics was founded in 2014.
Where is Intellia Therapeutics’s headquarters located?
Intellia Therapeutics’s headquarters is located in Cambridge, CAM, GB.
When was Intellia Therapeutics’s last funding round?
Intellia Therapeutics’s most recent funding round was for $300M (USD) in November 2022.
How many employees does Intellia Therapeutics have?
Intellia Therapeutics has 598 employees as of Feb 6, 2024.
How much has Intellia Therapeutics raised to-date?
As of July 05, 2023, Intellia Therapeutics has raised a total of $1.2B (USD) since Nov 30, 2022.
Add Comparison
Total Raised to Date
$1.2B
USD
Last Update Nov 30, 2022
Last Deal Details
$300M
USD
Nov 30, 2022
Post Ipo Equity
Total Employees Over Time
598
As of Feb 2024
Intellia Therapeutics Address
Cambridge,
Cambridgeshire
United Kingdom
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts